Xinvento aims to alleviate the difficulties associated with Congenital Hyperinsulinism (CHI) by developing an effective treatment to overcome the current difficulties of limited effective treatment options available to patients.
Xinvento has 1 recorded funding round in the Tech.eu database (amounts undisclosed). Based in Amsterdam, Netherlands; active in Healthtech. Acquired by Rhythm Pharmaceuticals in 2023. Data as of 7 Aug 2026.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-04-26 | Seed | — | Daniel de Boer,David Meeker,Dinko Valerio,Ed Kaye,Hans Schikan,James Shannon+2 more | View deal → |
